This page describes the PuMP Trial, which is investigating the safety and effectiveness of MVR-C5252, an experimental oncolytic virus therapy, in adults with recurrent high-grade glioma. Participants will undergo imaging, biopsies, and receive the drug through an implanted catheter system to assess its impact on tumor response and immune activation.
Dr. Khasraw is leading the PuMP Trial. He oversees the study’s design, patient enrollment, and clinical evaluations to determine the safety profile and therapeutic potential of MVR-C5252 in treating malignant gliomas.
Read the full article here.